U.S. Logistics Stock News

NasdaqGS:CBSH
NasdaqGS:CBSHBanks

Assessing Commerce Bancshares (CBSH) Valuation After Recent Share Price Softness

Commerce Bancshares stock snapshot after recent performance Commerce Bancshares (CBSH) shares recently closed at US$48.07, with the stock showing a 1 day return of 1.88% and a past month decline of 5.73%, extending to 8.75% over the past 3 months. See our latest analysis for Commerce Bancshares. Stepping back, the recent softness in the 1 month share price return of 5.73% and 3 month share price return of 8.75% sits alongside a 1 year total shareholder return of 16.49%. This may indicate...
NYSE:HIMS
NYSE:HIMSHealthcare

Assessing Hims & Hers Health (HIMS) Valuation After A Sharp Pullback And Long Term Shareholder Gains

Recent performance snapshot Hims & Hers Health (HIMS) has drawn investor attention after a mixed run, with the share price near US$19.38 and returns ranging from a 33% gain over the past month to a 43% decline over the past 3 months. See our latest analysis for Hims & Hers Health. The recent pullback, including a 7.1% 1 day share price decline and weaker year to date share price return, sits against a much stronger 3 year total shareholder return of 95.4%. This suggests that momentum has...
NYSE:NCLH
NYSE:NCLHHospitality

Norwegian Cruise Line Governance Shakeup Raises Questions On Valuation And Debt

Norwegian Cruise Line Holdings (NYSE:NCLH) has entered a cooperation agreement with Elliott Investment Management. The company is appointing five new directors to the board, including leaders from travel, finance, and investment sectors. CEO John Chidsey is also becoming Board Chairman as part of the governance changes. Norwegian Cruise Line Holdings runs a global cruise operation, competing with other large operators for leisure travel demand. The cruise sector has been influenced by...
NasdaqCM:BTDR
NasdaqCM:BTDRSoftware

A Look At Bitdeer Technologies Group (BTDR) Valuation After New SEALMINER Launch And Mining Expansion

Why Bitdeer’s latest moves matter for BTDR stock Bitdeer Technologies Group (BTDR) has put fresh attention on its stock with two developments: a new SEALMINER DL1 Air Scrypt mining machine and unaudited February 2026 operating metrics showing expanded hash rate and mining activity. See our latest analysis for Bitdeer Technologies Group. The latest product launch and operating update come after a mixed year for investors. The share price is US$8.37, with a 1 month share price return of 8.7%,...
NasdaqGS:CSX
NasdaqGS:CSXTransportation

Assessing CSX (CSX) Valuation As Earnings Approach And US$670 Million Locomotive Deal Gains Attention

Why CSX’s upcoming earnings and locomotive upgrade matter now CSX (CSX) heads into its April 22 first quarter earnings report with attention on a recent US$670 million agreement with Wabtec to modernize its Evolution Series locomotive fleet for fuel efficiency and reliability gains. See our latest analysis for CSX. CSX’s 1-year total shareholder return of 38.35% and 3-year total shareholder return of 38.37% sit against a 9.37% year to date share price return and an 8.03% 90 day share price...
NYSE:PHIN
NYSE:PHINAuto Components

Assessing PHINIA (PHIN) Valuation After Recent Share Price Volatility

PHINIA stock at a glance PHINIA (PHIN) is catching investor attention after recent share price swings, with a last close at $67.11 and returns ranging from a 7% gain over the past week to a 7.6% decline over the month. See our latest analysis for PHINIA. Recent moves have been choppy, with a 7% 7 day share price return following a 7.6% 30 day share price decline. At the same time, the 1 year total shareholder return of 58.9% points to momentum that has been strong over a longer stretch. If...
NasdaqGM:OCS
NasdaqGM:OCSPharmaceuticals

Oculis Holding (NasdaqGM:OCS) Valuation In Focus After Positive Privosegtor Phase 2 Optic Neuritis Data

Privosegtor data presentation puts Oculis Holding (OCS) in focus Oculis Holding (NasdaqGM:OCS) is coming into focus after announcing that ACUITY Phase 2 data for its investigational therapy Privosegtor in acute optic neuritis will be presented at the NANOS 2026 meeting. See our latest analysis for Oculis Holding. At a share price of $24.69, Oculis has seen a 16.05% 1 month share price decline after strong longer term momentum, including a 23.45% 3 month share price return and a 232.30% 3 year...
NasdaqGS:SMTC
NasdaqGS:SMTCSemiconductor

A Look At Semtech’s Valuation After Recent Share Pullback

What Semtech’s Recent Share Performance Tells You Semtech (SMTC) has drawn investor attention after a recent pullback, with the share price down 2.7% over the past day and about 20% over the past month, despite strong longer term returns. See our latest analysis for Semtech. The recent 30 day share price return of a 20% decline, alongside a 4.1% year to date share price decline, contrasts with a 1 year total shareholder return of 105.9%. This suggests that momentum has cooled after a strong...
NasdaqGS:DIOD
NasdaqGS:DIODSemiconductor

A Look At Diodes (DIOD) Valuation After New Automotive MOSFET Expansion

Diodes (DIOD) is back on investor radar after expanding its PowerDI8080-5 automotive-compliant N-channel MOSFET line with a new ultra-low RDS(ON) 100V device aimed at demanding electric vehicle systems. See our latest analysis for Diodes. The product launch arrives after a strong 90 day share price return of 36.35% and a 1 year total shareholder return of 57.43%. However, the 3 and 5 year total shareholder returns remain negative, suggesting recent momentum is building off a weaker long term...
NYSE:TTAM
NYSE:TTAMBasic Materials

A Look At Titan America (TTAM) Valuation After Recent Share Price Volatility

Recent price moves and business snapshot Titan America (TTAM) has drawn investor attention after recent price swings, with the share price at $14.82 and returns ranging from a 4.4% gain over the past week to an 18.2% decline over the month. For context, Titan America SA generates US$1.66b in revenue, all from the United States, and reports net income of US$185.44m across its Florida and Mid Atlantic business segments. See our latest analysis for Titan America. The recent 18.2% 1 month share...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

Assessing GlobalFoundries (GFS) Valuation After New U.S. Patent Lawsuits Against Tower Semiconductor

GLOBALFOUNDRIES (GFS) has moved into the spotlight after filing multiple U.S. patent infringement lawsuits against Tower Semiconductor, a legal step that puts its manufacturing know how and intellectual property protections front and center for investors. See our latest analysis for GLOBALFOUNDRIES. The legal action lands at a time when the share price is US$42.94, with a 19.78% 90 day share price return and a 16.40% 1 year total shareholder return, contrasting with a 3 year total shareholder...
NYSE:CACI
NYSE:CACIProfessional Services

Is It Time To Reassess CACI International (CACI) After The Recent Share Price Pullback

For investors wondering if CACI International at around US$563 per share still offers value after a strong run, this article explains what the current price may be implying about the stock. The share price is US$563.67 after a 7% decline over the last week and a 7.6% decline over the last month. Despite this, the 1 year return is 51%, and the 3 year and 5 year returns are 90.2% and 126.7% respectively. Recent coverage has focused on the stock's strong multi year performance and the pullback...
NasdaqGS:MSFT
NasdaqGS:MSFTSoftware

Microsoft Pairs AI Training Push With Internal HR Reorganization For Investors

Microsoft and the National Association of Workforce Boards are partnering to offer free, practical AI skills training to U.S. workforce agencies and job seekers. The training aims to help local workforce boards and employment centers integrate AI tools into job search support and career services. Separately, Microsoft is reorganizing its human resources department, combining teams focused on pay, workplace norms, culture, and related leadership roles. The HR overhaul is intended to...
NYSE:AROC
NYSE:AROCEnergy Services

Is It Too Late To Consider Archrock (AROC) After A 7x Multi Year Run?

If you are wondering whether Archrock's recent share price puts it on sale or already fully priced, it helps to step back and look carefully at what the current valuation actually reflects. At a last close of US$35.52, the stock has returned 0.5% over the past month, 33.4% year to date and 38.7% over the last year. The 3 year and 5 year returns are very large at more than 7x and around 7x respectively, which naturally raises questions about how much future upside or risk is now baked...
NasdaqGS:WDFC
NasdaqGS:WDFCHousehold Products

Assessing WD-40 (WDFC) Valuation After Recent Share Price Weakness

WD-40 stock moves after recent share performance WD-40 (WDFC) has drawn fresh attention after recent share performance, with the stock down about 2% over the past day, 6% over the past week, and 16% over the past month. See our latest analysis for WD-40. That recent slide sits against a mixed backdrop, with a 1 year total shareholder return of about 15% decline but a 3 year total shareholder return of roughly 19% gain, so recent momentum looks weaker than the longer term picture. If WD-40’s...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Is Vera Therapeutics (VERA) Pricing Reflect Its DCF Upside After Recent Share Price Weakness

If you are wondering whether Vera Therapeutics at around US$38.86 is priced purely on its story or still leaves some value on the table, this article walks through what the current share price actually implies. The stock has had a mixed run, with a 4.1% decline over the past week and a 4.7% decline over the past month, yet it still shows a 45.9% return over the last year and a very large return over three years. Recent attention on Vera Therapeutics has focused on its position in the biotech...
NYSE:ONTO
NYSE:ONTOSemiconductor

The Bull Case For Onto Innovation (ONTO) Could Change Following Dragonfly G5 HBM4 Inspection Wins - Learn Why

Earlier this month, Onto Innovation Inc. launched its Dragonfly G5 inspection and metrology system, securing double-digit orders from a high bandwidth memory manufacturer for HBM4 ramp, with shipments scheduled to begin in the second quarter of 2026. The Dragonfly G5’s finer defect sensitivity, higher throughput, and expanded machine learning capabilities highlight how Onto Innovation is deepening its role in advanced semiconductor packaging process control. Next, we’ll explore how the...
NasdaqGM:WRD
NasdaqGM:WRDAuto Components

WeRide Buyback Links Slovakia Expansion And NVIDIA GTC Spotlight To Valuation

WeRide, listed as NasdaqGM:WRD, has launched a share repurchase program covering up to 10% of its issued share capital. In addition, the buyback follows the company’s recent entry into Slovakia to roll out what it calls the country’s first autonomous vehicle initiative. WeRide also presented its next generation Robotaxi at NVIDIA GTC 2026, highlighting its technical partnership and product roadmap. For anyone tracking autonomous driving, WeRide sits at the intersection of software, hardware...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Apple Expands US Manufacturing As Investors Weigh Valuation And Momentum

Apple (NasdaqGS:AAPL) is expanding its American Manufacturing Program with new U.S. based partners. The company is adding Bosch, Cirrus Logic, TDK and Qnity Electronics to support domestic production of advanced components. TDK is preparing to produce critical iPhone parts in the U.S. for the first time, alongside joint investment in advanced semiconductor technologies. For you as an investor following Apple, this move sits at the intersection of hardware, supply chains and policy. Apple is...
NYSE:CXT
NYSE:CXTElectronic

Has Crane NXT (CXT) Fallen Too Far After Recent Share Price Weakness?

If you are wondering whether Crane NXT is attractively priced or just a value trap, starting with a clear view of its recent share performance and fundamentals can help frame the question. The stock last closed at US$41.15, with a 1.9% gain over the past week, a 14.8% decline over the past month, a 13.8% decline year to date, and a 18.8% decline over the last year. Its 3 year return sits at 9.4%. Recent coverage has focused on providing evergreen context for Crane NXT, aiming to keep...
NYSE:AB
NYSE:ABCapital Markets

Is AllianceBernstein (AB) Fairly Priced After Recent Share Price Declines?

Wondering whether AllianceBernstein Holding at around US$35.66 is priced attractively, too expensive, or somewhere in between? This article walks through the key signals that matter for you as a shareholder or potential investor. The stock has seen mixed returns, with a 3.9% decline over the past week, a 9.2% decline over the last 30 days, a 7.7% decline year to date, but a 1.0% return over 1 year and gains of 26.7% over 3 years and 31.8% over 5 years. These moves have come as investors...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Alphabet (GOOGL) Valuation Check After A Multi Year Share Price Run

Alphabet shares after a strong multi year run Alphabet (GOOGL) stock has pulled back recently, with a 2.3% decline over the past day, 8.9% over the week, and about 12% over both the past month and past 3 months. See our latest analysis for Alphabet. Alphabet’s recent pullback has come after a very strong run, with momentum clearly fading in the short term, while the 1 year total shareholder return of 78.38% and 3 year total shareholder return of 166.66% still reflect substantial gains. If...
NYSE:SCCO
NYSE:SCCOMetals and Mining

Is It Too Late To Consider Southern Copper (SCCO) After The Recent 25.8% Pullback?

Wondering whether Southern Copper at around US$162 a share still makes sense for your portfolio, or if the easy gains are already behind it. The stock has returned 6.1% over the last 7 days, while the 30 day return sits at a 25.8% decline and the 1 year return stands at 83.6%, with longer 3 and 5 year returns of 149.7% and 208.1%. Recent market attention has focused on Southern Copper as part of a broader interest in large copper producers and their role in supply for global industry. That...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success

Why the brepocitinib data matters for Roivant Sciences (ROIV) The Phase 3 VALOR trial results for brepocitinib in dermatomyositis, published in the New England Journal of Medicine and paired with an FDA Priority Review, put a key Roivant Sciences (ROIV) asset firmly in focus for investors. See our latest analysis for Roivant Sciences. Roivant’s recent brepocitinib milestones arrive after a 1 year total shareholder return of 155.49% and a 3 year total shareholder return of 259.35%. The share...